先天性心脏缺陷或心律失常胎儿中用于诊断胎儿心力衰竭的母体生物标志物
该探索性横断面研究纳入50例先天性心脏缺陷或心律失常单胎及50例对照,分析孕晚期母体血清2种激素和36种细胞因子。发现肿瘤坏死因子-α、血管内皮生长因子-D和肝素结合表皮生长因子样生长因子与胎儿心力衰竭独立相关,三者联合敏感度100%、特异度80.3%。
要点
- 肿瘤坏死因子-α、血管内皮生长因子-D和肝素结合表皮生长因子样生长因子与胎儿心力衰竭独立相关。
- 三项细胞因子联合诊断胎儿心力衰竭的敏感度为100%,特异度为80.3%。
- 无胎儿心力衰竭时,先天性心脏缺陷与对照的母体血清细胞因子和激素浓度相似。
核心结论
- 母体血清肿瘤坏死因子-α、血管内皮生长因子-D和肝素结合表皮生长因子样生长因子浓度与胎儿心力衰竭相关。
研究设计与样本
- 探索性横断面研究,在三级儿科心脏中心开展,纳入2013年至2016年国家脑心血管中心生物样本库登记的50例先天性心脏缺陷或心律失常单胎及50例对照。
- 孕晚期采集母体血清,使用Bio-Plex Pro人类癌症生物标志物面板1和2分析2种激素和36种细胞因子。
- 胎儿心力衰竭定义为心血管轮廓评分≤7分。
主要发现
- 37例先天性心脏缺陷胎儿中1例三尖瓣发育不良伴中度三尖瓣反流发生心力衰竭;13例心律失常胎儿中5例在孕28-33周发生心力衰竭。
- 孕28-33周胎儿心力衰竭组(n=6)较无心力衰竭组(n=61)母体血清肿瘤坏死因子-α、白细胞介素-6、可溶性Fas配体、转化生长因子-α和血管内皮生长因子-D浓度显著升高(P<.05),肝素结合表皮生长因子样生长因子浓度显著降低(P<.05)。
- 多因素分析显示母体血清肿瘤坏死因子-α、血管内皮生长因子-D和肝素结合表皮生长因子样生长因子与胎儿心力衰竭独立相关。
- 无胎儿心力衰竭时,先天性心脏缺陷胎儿与对照的母体血清所有细胞因子和激素浓度相似,而可溶性CD40配体浓度仅在胎儿心律失常中升高。
关键数值与推荐
- 肿瘤坏死因子-α截断值68 pg/mL,敏感度50.0%,特异度93.4%,阳性似然比7.6,阴性似然比0.5。
- 血管内皮生长因子-D截断值1156 pg/mL,敏感度50.0%,特异度93.4%,阳性似然比7.6,阴性似然比0.5。
- 肝素结合表皮生长因子样生长因子截断值90 pg/mL,敏感度83.3%,特异度83.6%,阳性似然比5.1,阴性似然比0.2。
- 三项细胞因子联合敏感度100%,特异度80.3%,阳性似然比5.1,阴性似然比0。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnosis of fetal heart failure depends primarily on fetal ultrasonography assessment. Our recent study demonstrated that plasma natriuretic peptide levels in umbilical cord blood were correlated with the severity of heart failure in fetuses with congenital heart defects or arrhythmias. However, percutaneous umbilical blood sampling is an invasive procedure, and therefore, less or noninvasive biomarkers reflecting fetal heart failure are required. OBJECTIVE: The aim of this study was to investigate the possibility of whether maternal serum biomarkers can diagnose fetal heart failure in fetuses with congenital heart defects or arrhythmias. STUDY DESIGN: This exploratory cross-sectional study was conducted at a tertiary pediatric cardiac center. A total of 50 singletons with fetal congenital heart defects or arrhythmias and 50 controls who were registered in the National Cerebral and Cardiovascular Center Biobank from 2013 to 2016 were included. Maternal serum samples obtained during the third trimester were analyzed for 2 hormones and 36 cytokines using the Bio-Plex Pro Human Cancer Biomarker panels 1 and 2. We comprehensively analyzed the association between maternal serum biomarkers and ultrasonography findings or fetal arrhythmia status. Fetal heart failure was defined as a cardiovascular profile score ≤7. RESULTS: Of 37 fetuses with congenital heart defects, heart failure was found in 1 case of tricuspid valve dysplasia with moderate tricuspid regurgitation. Of 13 fetuses with arrhythmias, 5 had heart failure at 28-33 weeks of gestation. Maternal serum cytokine and hormone concentrations were compared between patients with and without fetal heart failure at 28-33 weeks of gestation (n = 6 and n = 61, respectively). Sixty-one fetuses without heart failure consisted of 10 with congenital heart defect, 6 with arrhythmia, and 45 controls. Maternal serum concentrations of tumor necrosis factor-α, interleukin-6, soluble Fas ligand, transforming growth factor-α, and vascular endothelial growth factor-D were significantly higher when fetuses had heart failure than when they did not (P < .05), whereas maternal serum concentrations of heparin-binding epidermal growth factor-like growth factor were significantly lower when fetuses had heart failure than when they did not (P < .05). Multivariate analysis showed that maternal serum concentrations of tumor necrosis factor-α, vascular endothelial growth factor-D, and heparin-binding epidermal growth factor-like growth factor were independently associated with fetal heart failure. The cutoff values were as follows: tumor necrosis factor-α, 68 pg/mL (sensitivity of 50.0%, specificity of 93.4%, positive likelihood ratio of 7.6, negative likelihood ratio of 0.5); vascular endothelial growth factor-D, 1156 pg/mL (sensitivity of 50.0%, specificity of 93.4%, positive likelihood ratio of 7.6, negative likelihood ratio of 0.5); and heparin-binding epidermal growth factor-like growth factor, 90 pg/mL (sensitivity of 83.3%, specificity of 83.6%, positive likelihood ratio of 5.1, negative likelihood ratio of 0.2). The combination of these 3 cytokines showed sensitivity of 100%, specificity of 80.3%, positive likelihood ratio of 5.1, and negative likelihood ratio of 0. In the absence of fetal heart failure, concentrations of all maternal serum cytokines and hormones were similar in cases of fetal congenital heart defects and controls, while maternal serum soluble CD40 ligand concentrations were increased only in fetal arrhythmias. CONCLUSION: Maternal serum concentrations of tumor necrosis factor-α, vascular endothelial growth factor-D, and heparin-binding epidermal growth factor-like growth factor were associated with fetal heart failure.
引用
- Miyoshi T, Hosoda H, Nakai M, et al. Maternal biomarkers for fetal heart failure in fetuses with congenital heart defects or arrhythmias. Am J Obstet Gynecol. 2018. PMID: 30273582. doi:10.1016/j.ajog.2018.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。